Background and Aim: Proton pump inhibitors are effective for the treatment of gastric ulcers after endoscopic submucosal dissection (ESD). However, the most excellent therapy is controversial. Vonoprazan, an active potassium-competitive acid blocker, has a strong gastric acid secretion inhibitory effect, but its efficacy for the treatment of post-ESD gastric ulcers is unclear. Herein, we aimed to determine the healing effect of vonoprazan on post-ESD gastric ulcers.
INTRODUCTION

E NDOSCOPIC SUBMUCOSAL DISSECTION (ESD)
is widely carried out as a treatment for early gastric cancer and adenoma. 1, 2 As a result of resection, artificial ulcers are created after ESD. These ulcers sometimes cause complications, such as delayed bleeding and perforation. To prevent these complications, the ulcers should be healed as fast as possible. As the inhibition of gastric acid secretion can enhance the healing of such ulcers, giving a proton pump inhibitor (PPI) is recommended after ESD. [3] [4] [5] Although PPI have been proven to shrink such ulcers, some ulcers do not heal. 6, 7 Thus, a more effective therapy is needed.
Among conventional PPI, esomeprazole has a relatively strong inhibitory effect on gastric acid secretion.
Esomeprazole is an S-isomer of omeprazole and was the first PPI to be developed as an optical isomer. Further improvement of its pharmacokinetics has enabled a stronger inhibitory effect on gastric acid secretion and a reduction in inter-individual variability, compared with omeprazole. 8 Several reports have demonstrated that esomeprazole is significantly effective for the healing of reflux esophagitis. 8 In contrast, in terms of a beneficial effect for artificial gastric ulcers, the superiority of esomeprazole over omeprazole has not been determined. 9 Recently, a novel suppressant of gastric acid secretion called vonoprazan (TAKECAB; Takeda Pharmaceutical Company Ltd, Tokyo, Japan), which is an active potassium-competitive acid blocker (P-CAB), has been developed. Similar to PPI, P-CAB inhibit gastric H + /K + -ATPase; unlike PPI, however, P-CAB inhibit the enzyme in a K + -competitive and reversible manner. 10 Vonoprazan reportedly has a stronger and longer anti-secretory effect on H + /K + -ATPase than conventional PPI. 11, 12 Vonoprazan is also reportedly effective for the healing of gastric acid-related diseases, such as reflux esophagitis and gastroduodenal ulcers, as well as for eradicating Helicobacter pylori (H. pylori); however, its effect on artificial gastric ulcers is unknown. 13 As vonoprazan has a stronger suppressive effect on gastric acid secretion than conventional PPI, it may enhance the healing of post-ESD gastric ulcers to a greater extent than other PPI. Based on this hypothesis, the present study examined the effects of vonoprazan and esomeprazole on the healing of post-ESD gastric ulcers.
METHODS
Study design
T HIS STUDY WAS a prospective, single-center, twoarm, randomized controlled trial (RCT). The study protocol was approved by the ethical review board of Machida Municipal Hospital, Tokyo, Japan. The protocol was registered with the University hospital Medical Information Network (UMIN) entitled 'A randomized, comparative study of vonoprazan and esomeprazole 20 mg in the treatment of gastric ulcers due to endoscopic submucosal dissection (ESD) for gastric mucosal cancer' (registration number UMIN000017077). The study was conducted in accordance with the Helsinki Declaration, and written informed consent was obtained from all subjects prior to treatment.
Patients
A total of 92 patients were enrolled between April 2015 and June 2016 (Fig. 1) . In this trial, participants undergoing ESD for the treatment of early gastric cancer or adenoma at Machida Municipal Hospital were eligible.
We excluded patients who met any of the following: (i) hypersensitivity to vonoprazan or esomeprazole; (ii) taking medicine that could interact with vonoprazan or esomeprazole, such as other PPI, H2 receptor antagonists, mucosal Figure 1 Flow diagram showing the progress through the randomized trial comparing two treatment groups. Ninety-two patients scheduled to undergo endoscopic submucosal dissection (ESD) for gastric cancer or adenoma were enrolled after they had provided informed consent. Of these patients, 90 were randomly assigned to either a vonoprazan (20 mg/day) group (n = 45, V group) or an esomeprazole (20 mg/day) group (n = 45, E group); two patients who declined to participate in the study were excluded. The treatment period was 8 weeks. Six patients in the V group and four patients in the E group discontinued the intervention because of surgical treatment, aspiration pneumonia, treatment for another cancer, or the absence of a gastric neoplasm. We eventually analyzed 39 patients from the V group and 41 patients from the E group.
protective anti-ulcer drugs, or steroids; (iii) pregnant or lactating; (iv) impossibility of oral intake; (v) past history of resection of upper gastrointestinal (GI) tract; or (vi) taking contraindicated drugs. We set these criteria to ensure the safety of the subjects and to evaluate the test drugs appropriately.
Protocol
Patients were admitted to hospital on the day before ESD and were discharged 8 days after ESD. Each patient was interviewed to obtain their characteristics, such as age, sex, height, weight, past history, comorbidities, drugs, smoking history, and alcohol habits. We instructed patients to stop smoking and drinking alcohol until their post-ESD ulcer healed. H. pylori infection status was examined using the urea breath test and serological test. When either test was positive, the patient was defined as positive for H. pylori infection. All post-eradication patients had passed more than 1 year since the eradication of H. pylori. Degree of gastric mucosal atrophy was classified using the Kimura and Takemoto classification.
14 Tumor locations were divided into three regions: upper (cardia, fornix, and upper third of body), middle (middle and lower of body and angle), and lower third (antrum). Ulcer stages were classified using the Sakita and Miwa scale (Table 1) . 15 Before ESD, eligible patients were assigned in a 1:1 manner to either the vonoprazan group (V group) or the esomeprazole group (E group) according to a randomization procedure stratified according to age and sex and based on a random number table created on a computer. This randomization was done by a staff member who was not involved in the ESD or medication. In addition, the physicians evaluating ulcer size were blinded to the group assignments.
All patients underwent ESD and were given an i.v. injection of omeprazole (20 mg) twice daily on the day of ESD and on the following day. Two days after ESD, 20 mg vonoprazan (V group) or 20 mg esomeprazole (E group) was given orally daily for 8 weeks. All the patients underwent endoscopies at 1, 2, 4, 6, and 8 weeks after ESD to evaluate the size and condition of artificial ulcers. Major and minor axes of the ulcers were measured using a circular scale, 10 mm in diameter, made from a punched medical glove (Fig. 2) . Ulcer measurements were decided after a conference between two expert endoscopists. Ulcer area was calculated using the following formula:
(major axis/2) Â (minor axis/2) Â pðmm 2 Þ
ESD
We carried out ESD without withdrawal of daily anticoagulant monotherapy and/or non-steroidal anti-inflammatory drugs (NSAIDs). We carried out ESD using a single-channel endoscope (GIH-Q260J; Olympus Corporation, Tokyo, Japan) or a multi-bending two-channel endoscope (GIF-2TQ260M; Olympus). A Triangle Tip Knife (KD-640L; Olympus) was used, and an electrosurgical current was applied using an electrosurgical generator (ESG-100; White scar with complete re-epithelialization Figure 2 Major and minor axes of the artificial ulcers were measured, and the artificial ulcer area was calculated using circular scales, 10 mm in diameter, made from a punched medical glove.
Olympus). A mixture of glycerol, 0.1% indigocarmine, and 0.001% epinephrine was injected into the submucosal layer using a 23-gauge needle (NM-610U-0523; Olympus). Visible vessels were clipped and/or heat-coagulated using hemostatic forceps (Coagrasper, FD-410LR; Olympus).
Endpoint
Primary endpoint of the study was scar stage rate for artificial ulcers at 8 weeks after ESD. 15 Scar stage rate was defined as cure rate. Secondary endpoints were shrinkage rates of the artificial ulcers at 1, 2, 4, 6, and 8 weeks and complications after ESD, such as delayed bleeding or perforation. Shrinkage rates were calculated using the following formula: Delayed bleeding was defined as a clinical episode of hematemesis and/or melena, and/or a reduction in hemoglobin level ≥2 mg/dL occurring within 8 weeks after ESD. 16, 17 Sample power
Efficacies of vonoprazan and esomeprazole as monotherapies for post-ESD gastric ulcers have not been previously compared. Reportedly, the cure rates of omeprazole plus rebamipide and of esomeprazole plus rebamipide at 4 weeks after ESD were 38.7% and 27.6%, respectively; this difference was not statistically significant. 9 In a recent propensity score-matching analysis, the cure rates of vonoprazan plus rebamipide and of esomeprazole plus rebamipide at 4 weeks after ESD were 32% and 13%, respectively (P = 0.07). 18 In a recent RCT, the cure rate of PPI plus rebamipide at 8 weeks after ESD was 86.7%, whereas that of PPI monotherapy was 54.8% (P = 0.006). 6 We hypothesized that esomeprazole would be equivalent to other PPI and that vonoprazan would be superior to PPI monotherapy, similar to treatment with a PPI plus rebamipide, for the healing of artificial ulcers. Based on these RCT findings and assuming an a-error <0.05 and power at 0.8, at least 37 patients per group would be needed to show a between-group difference. Assuming a study drop-out rate of about 10%, we enrolled 45 patients per arm.
Statistical analysis
We used Fisher's exact test to compare the proportions of categorical variables (such as sex, drinking, smoking, drug intake, comorbidities, H. pylori infection, atrophic gastritis, tumor location, tumor histopathology, tumor depth, complications, and cure rate). Mann-Whitney U-test was used to compare medians of continuous variables (such as age, body mass index [BMI], ulcer size, and shrinkage rates). Multivariate analysis using logistic regression was done using factors (age, sex, location, NSAIDs, H. pylori infection, ulcer size) thought to be related to ulcer healing. [19] [20] [21] [22] There were no missing scores in this study. All P-values were twosided, and P < 0.05 was considered statistically significant. All statistical analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R commander designed to add statistical functions frequently used in biostatistics. 23 
RESULTS
Characteristics of patients and tumors
A TOTAL OF 92 patients were enrolled in the present study. After two patients who declined to participate were excluded, 90 patients were randomly assigned so that there were 45 patients in each group. Some patients could not complete the study intervention for the following reasons: (i) conversion to surgical resection because the lesions did not fulfill the specifications outlined in the guidelines for ESD after a review by gastrointestinal pathology specialists (n = 4 in V group, n = 3 in E group); 24 (ii) treatment for aspiration pneumonia was necessary (n = 1 in V group); (iii) treatment for another cancer was necessary (n = 1 in V group); and (iv) the lesion was not a gastric neoplasm (n = 1 in E group) (Fig. 1) . They could not receive follow-up endoscopies, so we excluded them from the analysis. We finally analyzed 39 patients in the V group and 41 patients in the E group. Characteristics of the patients and the lesions are summarized in Table 2 ; there were no significant differences between the groups. Drug compliance was more than 90% among all the patients.
Cure rate and shrinkage rate of ulcers
The 8-week cure rate for artificial ulcers was significantly higher in the V group [37/39] (94.9%) than in the E group [32/41] (78.0%) (P = 0.049) (Fig. 3) . Reflecting the cure rate, the 8-week shrinkage rate was also significantly higher in the V group than in the E group (P = 0.037) (Fig. 4) . However, the shrinkage rates until 6 weeks were not significantly different between the groups (Fig. 4) .
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Factors associated with healing of ulcers
In a multivariate analysis that included age, sex, giving NSAIDs, H. pylori infection, tumor location, ulcer size, and giving vonoprazan, only giving vonoprazan was correlated with artificial ulcer healing at 8 weeks (odds ratio = 6.33; 95% CI = 1.21-33.20; P = 0.029) ( Table 3 ).
Complications
There were three patients (3/41, 7.3%) who had delayed bleeding after ESD and one patient (1/41, 2.4%) who had a perforation during ESD in the E group ( Table 2 ). All the delayed bleeding occurred within 1 week after ESD. All the complications were alleviated endoscopically or with medication, and neither blood transfusions nor surgery were required. Although no complications occurred in the V group, the incidence of complications was not significantly different between the groups. No adverse events associated with the use of either drug were observed.
DISCUSSION
T HIS STUDY IS the first prospective RCT comparing vonoprazan and esomeprazole as monotherapies for the treatment of post-ESD gastric ulcers. Four main results were obtained. First, giving vonoprazan enhanced the healing of artificial ulcers to a greater extent than did esomeprazole. Second, no significant differences in shrinkage rates were observed until 6 weeks. Third, a multivariate analysis demonstrated that giving vonoprazan was the only factor associated with ulcer healing in this study. Finally, none of the patients experienced delayed bleeding in the V group, whereas three patients experienced this complication in the E group. Giving vonoprazan significantly improved the cure rate for artificial ulcers, compared with that of esomeprazole. This finding supports our hypothesis that the stronger inhibition of gastric acid secretion by vonoprazan may enhance the healing of artificial ulcers. To minimize the occurrence of complications after ESD, artificial ulcers should be healed without fail. Kakushima et al. reported that with conventional PPI, post-ESD gastric ulcers healed within 8 weeks regardless of ulcer size and location. 25, 26 Nevertheless, healing cannot be achieved in some cases even after 8 weeks of conventional PPI therapy. 6, 7 Previous RCT show the cure rates of post-ESD gastric ulcer using conventional PPI as 54.8% to 89.6%. 6, 27, 28 One reported approach to the treatment of such refractory ulcers was a combination therapy consisting of mucosal protective antiulcer drugs, such as rebamipide or polaprezinc, and a PPI. 6, 7 However, the benefit of combination therapy remains controversial. 29 In contrast, we showed that giving vonoprazan improved the cure rate of post-ESD ulcers at 8 weeks despite its use as a monotherapy. This finding indicates that vonoprazan monotherapy may be superior to conventional PPI for the enhanced healing of artificial ulcers.
To examine the proper treatment duration, we analyzed the time course of the healing process of the artificial ulcers. In the present study, no significant differences in shrinkage rates were found between the groups until 6 weeks. At 8 weeks, however, the V group had a significantly superior shrinkage rate than the E group, reflecting the results of the cure rates. Therefore, although an 8-week administration period is still necessary, these findings suggest that vonoprazan is able to enhance the healing of artificial ulcers to a greater extent than esomeprazole. These results indicate that giving vonoprazan required at least 8 weeks to heal artificial ulcers.
As this study was designed as a prospective RCT, univariate analyses did not reveal any significant differences in characteristics between the groups (Table 2) . One important characteristic that could potentially affect patient outcome is CYP2C19 genotype. Although we did not determine the genotypes of the patients, as the CYP2C19 genotype reportedly does not change the pharmacokinetics Figure 4 Shrinkage rates of artificial ulcers after endoscopic submucosal dissection (ESD) in both groups. , V group; , E group. NS, not significant. , and ulcer location, can prolong ulcer healing. [19] [20] [21] [22] We carried out a multivariate analysis including these factors and confirmed that the difference in the drug given was the only factor that contributed to the difference in the 8-week cure rates after ESD in the present study. This finding supports the adequacy of this study design.
In this trial, three patients in the E group experienced delayed bleeding (3/41, 7.3%). The reported frequency of delayed bleeding ranges from 5% to 8.9%. 16, 17, 33 Thus, the frequency of delayed bleeding in the present study was within an acceptable range, compared with previous reports. Although a statistically significant difference was not observed, the absence of patients with delayed bleeding in the V group does suggest that vonoprazan may be better at preventing delayed bleeding, compared with esomeprazole.
Previous reports that were not designed as RCT showed that vonoprazan plus rebamipide significantly enhanced the shrinkage rate of artificial ulcers, compared with esomeprazole plus rebamipide; 18 furthermore, vonoprazan plus polaprezinc significantly reduced the incidence of delayed bleeding, compared with rabeprazole plus polaprezinc. 34 These findings may have been influenced by the use of combination therapy. Here, we carried out an RCT and demonstrated that vonoprazan had a superior cure rate and potential for preventing delayed bleeding even when given as a monotherapy.
The only limitation of the present study is that it was carried out at a single center. Because the skill level of endoscopists and the background of the patients could have affected the results, further study at multiple centers is needed.
In conclusion, this trial revealed that giving vonoprazan was significantly superior to that of esomeprazole for the healing of gastric ulcers after ESD. Additionally, vonoprazan may be better at preventing delayed bleeding than esomeprazole. Vonoprazan should be considered as a treatment of first choice for the healing of artificial ulcers. For high-risk cases, in particular, the dramatic improvement in the cure rate for artificial ulcers enabled by vonoprazan could make ESD a safer treatment. 
